Last edition
News about
Innocan Pharma Submits Application for FDA Pre-IND Meeting for CBD Therapy to Combat Chronic Pain
The global pain therapeutics market, expected to surpass USD 100 billion by 2032, highlights the pressing need for effective alternatives to opioid-based treatments.
Lilly Acquires New Injectable Medicine Manufacturing Facility from Nexus
Eli Lilly has signed a definitive agreement with Nexus Pharmaceuticals wherein Lilly will be acquiring a manufacturing facility from Nexus.
Panasonic and Shinobi Therapeutics to Develop iPS Cell Therapy Manufacturing Tech
Shinobi Therapeutics has joined hands with Panasonic Holdings Corp. and Kyoto University's Center for iPS Cell Research and Application (CiRA).
PharmaLogic Opens New Radiopharmaceutical Production Facility in Cincinnati
PharmaLogic Holdings Corp. has opened its new radiopharmaceutical production and research facility in Cincinnati, Ohio.
Lantern Pharma Gets Regulatory Approval to Expand Harmonic Clinical Trial for NSCLC
Lantern Pharma Inc. has secured regulatory approval to expand its Harmonic trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan.
Ipsen and Skyhawk Therapeutics to Work on RNA Targeting Research in Rare Neurological Diseases
Ipsen has signed an exclusive worldwide collaboration with Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
Lupin Launches Mirabegron Extended-Release Tablets in US
Lupin Ltd. has developed Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received approval from the United States Food and Drug Administration (US FDA).
Essential Pharma Acquires Reminyl Oral Capsules
Essential Pharma has completed the acquisition of Reminyl oral capsules from Janssen Pharmaceutica NV.
SIIPL Signs Licensing Agreement with University of Oxford for Meningitis-B Vaccine
Serum Institute of India Pvt. Ltd. (SIIPL) and the University of Oxford have formalised a Licence of Technology Agreement negotiated by Oxford University Innovation in a significant stride towards addressing the challenge of Men-B disease.
Genentech Receives Approval from FDA for Alecensa
Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy